In my (very biased) opinion i remain of the view that...

In my (very biased) opinion i remain of the view that forecasting only 6 WISE devices being implanted in the first year per practise (for each of the 45 practises of which all have already participated in the initial SOLVE-CRT rollout trial) is far too conservative, bearing in mind the quality of life significance of the device, and the substantial unmet market demand that only the WISE device can service. (And notwithstanding its likely complementary link with existing pacemakers from each of Medtronics, Boston Scientific and Abbott Laboratories).
Of course we will only know that initial demand closer to commercial start up, as the planned sales force prepares and plans for that rollout.

Agreed that revenue doesn't equal profit, and my original share valuation assumed initial costs etc with an overall margin of (from a deteriorating memory) 40%, plus additional corporate costs etc, rising yearly up to 60% after 3 years.